| Dr Erica Hutcheson Bass, MD | |
|
160 Fountains Blvd Ste B, Madison, MS 39110-6343 | |
| (601) 981-2525 | |
| (601) 981-3152 |
| Full Name | Dr Erica Hutcheson Bass |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 16 Years |
| Location | 160 Fountains Blvd Ste B, Madison, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366604100 | NPI | - | NPPES |
| 0520851 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0122X | Surgery - Plastic And Reconstructive Surgery | 22857 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mississippi Premier Plastic Surgery Pllc | 6204997679 | 5 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests administered by an expert.
A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.
› Verified 1 days ago
| Entity Name | North Sunflower Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891705133 PECOS PAC ID: 7618932294 Enrollment ID: O20041123000318 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests administered by an expert.
A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.
› Verified 1 days ago
| Entity Name | Mississippi Premier Plastic Surgery Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639320864 PECOS PAC ID: 6204997679 Enrollment ID: O20081203000564 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests administered by an expert.
A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.
› Verified 1 days ago
| Entity Name | North Sunflower Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1548581184 PECOS PAC ID: 7618932294 Enrollment ID: O20170607002172 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests administered by an expert.
A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erica Hutcheson Bass, MD 160 Fountains Blvd Ste B, Madison, MS 39110-6343 Ph: (601) 981-2525 | Dr Erica Hutcheson Bass, MD 160 Fountains Blvd Ste B, Madison, MS 39110-6343 Ph: (601) 981-2525 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests administered by an expert.
A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.
› Verified 1 days ago
Dr. William Dotie Jackson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 160 Fountains Blvd Ste B, Madison, MS 39110 Phone: 601-981-2525 Fax: 601-981-3152 | |
Dr. Rishi Ashok Roy, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 225 Coachmans Rd, Madison, MS 39110 Phone: 601-856-3137 | |
Somjade Jay Songcharoen, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 160 Fountains Blvd Ste B, Madison, MS 39110 Phone: 601-981-2525 Fax: 601-981-3152 | |
Frederick Cortney Sailes, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 160 Fountains Blvd Ste B, Madison, MS 39110 Phone: 601-981-2525 | |
Dr. Emile Anthony Picarella Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 160 Fountains Blvd Ste B, Madison, MS 39110 Phone: 601-981-2525 Fax: 601-981-3152 |